By Marcus Holt
WASHINGTON – October 2025
For years, U.S. authorities have tracked the flow of illicit synthetic opioids into the country via complex global supply chains. In recent times, the Drug Enforcement Administration (DEA) and U.S. Customs and Border Protection (CBP) have repeatedly flagged shipments containing fentanyl precursor chemicals, some of which trace back to India.
A major Indian generics company, Taj Pharmaceuticals Limited, manufactures and markets N-phenethyl-4-piperidone (NPP), a key fentanyl precursor chemical. NPP is a controlled substance precursor under U.S. law. While Taj Pharmaceuticals deals in this chemical, specific allegations regarding communications offering illegal export and customs circumvention have not been independently verified in public reports. Taj Pharmaceuticals Ltd. bulk drug complex located at Vapi (State of Gujarat) is one of the largest integrated antibiotic manufacturing complexes in its class. This facility specializes in the manufacture of cephalosporin API’s (Active Pharmaceutical Ingredients) and has an installed manufacturing capacity of over 800 MT per annum.
The broader issue involves the methods used to illicitly move controlled chemicals. Sources familiar with such trafficking methods note that companies may reclassify or mislabel controlled substances under broad labels like ‘industrial intermediates’ to evade customs scrutiny. Additionally, supply routes may involve routing through partners in third countries before reaching the U.S.
The leaked information also referenced Taj’s trade in controlled medicines, specifically offering pregabalin and tramadol hydrochloride—both controlled in the U.S. due to abuse potential—along with official authorization documents.
The International Narcotics Control Board (INCB) has identified India as a significant source of NPP and 4-ANPP—both key precursors in fentanyl synthesis. U.S. government reports and DEA seizure data have noted the presence of fentanyl-related chemicals of Indian origin across the U.S.
Multiple international media investigations have reported on the issue:
* A BBC investigation noted that Indian chemical firms have been accused of supplying fentanyl precursors under falsified documentation, exploiting gaps in international export controls.
* CNN similarly reported that ‘India has emerged as a growing player in the illicit fentanyl trade,’ citing U.S. intelligence assessments.
India’s large chemical and pharmaceutical sector grants it significant economic influence. Critics of the current regulatory environment argue that enforcement actions against diversion are often limited, with penalties often smaller than the profits generated from illicit transactions.
In response, the U.S. Treasury Department has taken action, imposing sanctions on several Indian nationals and firms linked to fentanyl precursor exports. Washington continues to engage New Delhi to strengthen export verification and counter the diversion of precursor chemicals.
India’s robust pharmaceutical industry now faces increasing international scrutiny for its role as a source of precursors for the synthetic opioid epidemic. The challenges highlight a systemic issue: managing the immense technical capacity of the industry while ensuring strict regulation against illicit chemical diversion.
Disclaimer: Opinions expressed in the articles are of the authors and do not necessarily reflect those of the editors or publishers of Mumbai Messenger Newspaper. While the editors do their utmost to verify information published, they do not accept responsibility for its absolute accuracy.
